medicine-news-1/cyberonics-announces-epilepsy-technology-collaborations-58767-1/;/a><br

Breaking Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2 NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3 Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2 Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3 Biomatrica Launches SampleWare 3.1 2 Biomatrica Launches SampleWare 3.1 3

[0] For Release: Esco Announces 2nd North American Facility in Marietta, OH [0] NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont [0] Brooks Instrument Appoints Mike Bayda as Global Level Product Manager [0] Biomatrica Launches SampleWare 3.1

Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6 Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5 GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3 Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4 IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1 IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2 Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1 Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 1 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 2 Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 3

[0] Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies [0] GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer [0] Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders